Erratum

No authors listed

Published Erratum

No authors listed. Cancer Sci. 2020 Sep.

. 2020 Sep;111(9):3402.

doi: 10.1111/cas.14628.

No abstract available

Erratum for

Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.
Morita Y, Maeda Y, Yamaguchi T, Urase F, Kawata S, Hanamoto H, Tsubaki K, Ishikawa J, Shibayama H, Matsumura I, Matsuda M. Morita Y, et al. Cancer Sci. 2018 Oct;109(10):3209-3215. doi: 10.1111/cas.13739. Epub 2018 Aug 26. Cancer Sci. 2018. PMID: 30007103 Free PMC article. Clinical Trial.

1. Morita Y, Maeda Y, Yamaguchi T, et al. Five‐day regimen of azacitidine for lower‐risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single‐arm phase 2 trial. Cancer Sci. 2018;109:3209‐3215. 10.1111/cas.13739 - DOI - PMC - PubMed